[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607986":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":29,"locations":37,"responsibleParty":169,"collaborators":11,"id":171,"slug":11,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":11,"eligibilityCriteria":176,"healthyVolunteers":172,"sex":177,"minAge":178,"maxAge":11,"enrollmentInfo":179,"targetDuration":11,"studyType":182,"phases":183,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":202},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"BMS-986506: Part 1A","EXPERIMENTAL",null,[13],"Drug: BMS-986506",{"label":15,"type":10,"description":11,"interventionNames":16},"BMS-986506: Part 2A",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"BMS-986506: Part 2B",[13],[21],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","BMS-986506","Specified dose on specified days",[9,15,18],[27],{"name":5,"affiliation":5,"role":28},"STUDY_DIRECTOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":36,"role":32,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[38,55,68,82,96,110,125,140,155],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Dana-Farber Cancer Institute","RECRUITING","Boston","Massachusetts","02215","United States",{"type":46,"coordinates":47},"Point",[48,49],-71.05977,42.35843,{"lat":49,"lon":48},[52],{"name":53,"role":32,"phone":54,"phoneExt":11,"email":11},"Stephanie Berg, Site 0006","617-632-4932",{"facility":56,"status":40,"city":57,"state":57,"zip":58,"country":44,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":46,"coordinates":60},[61,62],-74.00597,40.71427,{"lat":62,"lon":61},[65],{"name":66,"role":32,"phone":67,"phoneExt":11,"email":11},"Martin Voss, Site 0029","646-888-4721",{"facility":69,"status":40,"city":70,"state":71,"zip":72,"country":44,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Fox Chase Cancer Center","Philadelphia","Pennsylvania","19111",{"type":46,"coordinates":74},[75,76],-75.16362,39.95238,{"lat":76,"lon":75},[79],{"name":80,"role":32,"phone":81,"phoneExt":11,"email":11},"Elizabeth Plimack, Site 0002","215-728-3889",{"facility":83,"status":40,"city":84,"state":85,"zip":86,"country":44,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":46,"coordinates":88},[89,90],-86.78444,36.16589,{"lat":90,"lon":89},[93],{"name":94,"role":32,"phone":95,"phoneExt":11,"email":11},"Benjamin Garmezy, Site 0026","713-444-7804",{"facility":97,"status":40,"city":98,"state":99,"zip":100,"country":44,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"START San Antonio","San Antonio","Texas","78229",{"type":46,"coordinates":102},[103,104],-98.49363,29.42412,{"lat":104,"lon":103},[107],{"name":108,"role":32,"phone":109,"phoneExt":11,"email":11},"Amita Patnaik, Site 0001","210-593-5250",{"facility":111,"status":40,"city":112,"state":113,"zip":114,"country":115,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Arthur J.E. Child Comprehensive Cancer Centre","Calgary","Alberta","T2N 5G2","Canada",{"type":46,"coordinates":117},[118,119],-114.08529,51.05011,{"lat":119,"lon":118},[122],{"name":123,"role":32,"phone":124,"phoneExt":11,"email":11},"Daniel Heng, Site 0021","4035213166",{"facility":126,"status":40,"city":127,"state":128,"zip":129,"country":130,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Gustave Roussy","Villejuif","Val-de-Marne","94800","France",{"type":46,"coordinates":132},[133,134],2.35992,48.7939,{"lat":134,"lon":133},[137],{"name":138,"role":32,"phone":139,"phoneExt":11,"email":11},"Christophe Massard, Site 0008","+33142114211",{"facility":141,"status":40,"city":142,"state":143,"zip":144,"country":145,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Hospital Universitario Reina Sofia","Córdoba","Andalusia","14004","Spain",{"type":46,"coordinates":147},[148,149],-4.77275,37.89155,{"lat":149,"lon":148},[152],{"name":153,"role":32,"phone":154,"phoneExt":11,"email":11},"MARIA JOSE MENDEZ VIDAL, Site 0015","+34957011448",{"facility":156,"status":40,"city":157,"state":158,"zip":159,"country":145,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Hospital Universitari Vall d'Hebron","Barcelona","Barcelona [Barcelona]","08035",{"type":46,"coordinates":161},[162,163],2.15899,41.38879,{"lat":163,"lon":162},[166],{"name":167,"role":32,"phone":168,"phoneExt":11,"email":11},"Cristina Suarez Rodriguez, Site 0018","349327460004350",{"type":170,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100607986",false,"NCT07195682","A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)","A Phase 1\u002F1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)","Inclusion Criteria:\n\n* Participants must have histologically confirmed diagnosis of locally advanced or metastatic ccRCC.\n* For part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy.\n* For part 2: Participants must have had at least one standard treatment plan that included both a PD-1\u002FL1 inhibitor and a VEGF-TKI (either together or one after the other).\n* Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\nExclusion Criteria:\n\n* Participants with Inability to administer and\u002For tolerate oral medication without chewing, breaking, crushing, or otherwise altering the product dosage form.\n* For Part 2A: Participants who have received more than 3 prior systemic regimens for locally advanced or metastatic ccRCC including prior treatment with HIF2a inhibitors.\n* Participants who have hypoxia as defined by a pulse oximeter reading \\\u003C 92% at rest or requires intermittent or chronic supplemental oxygen.\n* Participants who have received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 28 days prior to the first dose of study intervention.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":180,"type":181},125,"ESTIMATED","INTERVENTIONAL",[184],"PHASE1","This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.",[187],"Renal Cell Carcinoma",[189,190,191,192],"Metastatic clear cell renal cell carcinoma","Advanced clear cell renal cell carcinoma","ccRCC","Kidney cancer","2026-06-08",{"date":195,"type":196},"2026-06-09","ACTUAL",{"date":198,"type":196},"2026-01-15",{"date":200,"type":181},"2031-04-03",{"name":5,"class":6},9]